First-in-Class Small Molecule Inhibitor of Oncogene AVIL in Glioblastoma
{{output}}
Glioblastoma multiforme (GBM) is the most prevalent and aggressive malignant primary brain tumor, marked by rapid growth, extensive invasiveness, and a median survival of only ∼15 months despite current multimodal therapy. To identify new therapeutic vulnerab... ...
